BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 28420725)

  • 1. Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine.
    Husain H; Melnikova VO; Kosco K; Woodward B; More S; Pingle SC; Weihe E; Park BH; Tewari M; Erlander MG; Cohen E; Lippman SM; Kurzrock R
    Clin Cancer Res; 2017 Aug; 23(16):4716-4723. PubMed ID: 28420725
    [No Abstract]   [Full Text] [Related]  

  • 2. A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2.
    Park CK; Cho HJ; Choi YD; Oh IJ; Kim YC
    Cancer Res Treat; 2019 Apr; 51(2):777-787. PubMed ID: 30189719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting osimertinib-treatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L).
    Sakai K; Takahama T; Shimokawa M; Azuma K; Takeda M; Kato T; Daga H; Okamoto I; Akamatsu H; Teraoka S; Ono A; Ohira T; Yokoyama T; Yamamoto N; Nakagawa K; Nishio K
    Mol Oncol; 2021 Jan; 15(1):126-137. PubMed ID: 33131198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating tumor DNA analysis of EGFR-mutant non-small cell lung cancer patients receiving osimertinib following previous tyrosine kinase inhibitor treatment.
    Beagan JJ; Bach S; van Boerdonk RA; van Dijk E; Thunnissen E; van den Broek D; Weiss J; Kazemier G; Pegtel DM; Bahce I; Ylstra B; Heideman DAM
    Lung Cancer; 2020 Jul; 145():173-180. PubMed ID: 32460198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma ctDNA monitoring during epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor treatment in patients with EGFR-mutant non-small cell lung cancer (JP-CLEAR trial).
    Usui K; Yokoyama T; Naka G; Ishida H; Kishi K; Uemura K; Ohashi Y; Kunitoh H
    Jpn J Clin Oncol; 2019 Jun; 49(6):554-558. PubMed ID: 30809659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors.
    Li C; Jia R; Liu H; Zhang B; Wang C
    Diagn Pathol; 2018 Aug; 13(1):49. PubMed ID: 30103780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
    Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
    Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA.
    Remon J; Caramella C; Jovelet C; Lacroix L; Lawson A; Smalley S; Howarth K; Gale D; Green E; Plagnol V; Rosenfeld N; Planchard D; Bluthgen MV; Gazzah A; Pannet C; Nicotra C; Auclin E; Soria JC; Besse B
    Ann Oncol; 2017 Apr; 28(4):784-790. PubMed ID: 28104619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating Tumor DNA T790M Testing as a Predictor of Osimertinib Efficacy in Epidermal Growth Factor Receptor Mutant Non-small Cell Lung Cancer: A Single Center Experience.
    Makarov M; Peled N; Shochat T; Zer A; Rotem O; Dudnik E
    Isr Med Assoc J; 2019 Jun; 21(6):394-398. PubMed ID: 31280508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The presence and variant allele fraction of EGFR mutations in ctDNA and development of resistance.
    O'Kane GM; Liu G; Stockley TL; Shabir M; Zhang T; Law JH; Le LW; Sacher A; Shepherd FA; Bradbury PA; Leighl NB
    Lung Cancer; 2019 May; 131():86-89. PubMed ID: 31027703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison of epidermal growth factor receptor (EGFR) gene T790M mutation by droplet digital PCR and Super-ARMS PCR in plasma ctDNA samples of non-small cell lung cancer patients with the resistance to EGFR-tyrosine kinase inhibitor].
    Cao ZY; Wu W; Hou LK; Zhang W; Gao CX; Wu CY; Zhang LP
    Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):910-914. PubMed ID: 30522170
    [No Abstract]   [Full Text] [Related]  

  • 12. Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC.
    Knebel FH; Bettoni F; Shimada AK; Cruz M; Alessi JV; Negrão MV; Reis LFL; Katz A; Camargo AA
    Lung Cancer; 2017 Jun; 108():238-241. PubMed ID: 28625643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients.
    Boysen Fynboe Ebert E; McCulloch T; Holmskov Hansen K; Linnet H; Sorensen B; Meldgaard P
    Lung Cancer; 2020 May; 143():67-72. PubMed ID: 32213382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of comprehensive analysis with circulating tumor DNA in advanced non-small cell lung cancer patients considered for osimertinib treatment.
    Sueoka-Aragane N; Nakashima C; Yoshida H; Matsumoto N; Iwanaga K; Ebi N; Nishiyama A; Yatera K; Kuyama S; Fukuda M; Ushijima S; Umeguchi H; Harada D; Kashiwabara K; Suetsugu T; Fujimoto N; Tanaka F; Uramoto H; Yoshii C; Nakatomi K; Koh G; Seki N; Aoe K; Nosaki K; Inoue K; Takamori A; Kawaguchi A
    Cancer Med; 2021 Jun; 10(12):3873-3885. PubMed ID: 33982444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy.
    Minari R; Bordi P; Del Re M; Facchinetti F; Mazzoni F; Barbieri F; Camerini A; Comin CE; Gnetti L; Azzoni C; Nizzoli R; Bortesi B; Rofi E; Petreni P; Campanini N; Rossi G; Danesi R; Tiseo M
    Lung Cancer; 2018 Jan; 115():21-27. PubMed ID: 29290257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osimertinib, a third-generation tyrosine kinase inhibitor targeting non-small cell lung cancer with EGFR T790M mutations.
    McCoach CE; Jimeno A
    Drugs Today (Barc); 2016 Oct; 52(10):561-568. PubMed ID: 27910964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor-positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment.
    Provencio M; Serna-Blasco R; Franco F; Calvo V; Royuela A; Auglytė M; Sánchez-Hernández A; de Julián Campayo M; García-Girón C; Dómine M; Blasco A; Sánchez JM; Oramas J; Bosch-Barrera J; Sala MÁ; Sereno M; Ortega AL; Chara L; Hernández B; Padilla A; Coves J; Blanco R; Balsalobre J; Mielgo X; Bueno C; Jantus-Lewintre E; Molina-Vila MÁ; Romero A
    Eur J Cancer; 2021 May; 149():61-72. PubMed ID: 33831609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective Observational Study of Treatment Resistance-related Gene Screening Using Plasma Circulating Tumor DNA in Third-generation EGFR-TKI Osimertinib Therapy (Elucidator).
    Tamiya A; Isa SI; Taniguchi Y; Nakagawa H; Atagi S; Ando M; Koh Y
    Clin Lung Cancer; 2021 May; 22(3):e336-e341. PubMed ID: 32641247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib.
    Ou SI; Cui J; Schrock AB; Goldberg ME; Zhu VW; Albacker L; Stephens PJ; Miller VA; Ali SM
    Lung Cancer; 2017 Jun; 108():228-231. PubMed ID: 28625641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world data on treatment outcomes in
    Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G
    Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.